1. Home
  2. RELI vs CERO Comparison

RELI vs CERO Comparison

Compare RELI & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RELI
  • CERO
  • Stock Information
  • Founded
  • RELI 2013
  • CERO 2017
  • Country
  • RELI United States
  • CERO United States
  • Employees
  • RELI N/A
  • CERO N/A
  • Industry
  • RELI Specialty Insurers
  • CERO
  • Sector
  • RELI Finance
  • CERO
  • Exchange
  • RELI Nasdaq
  • CERO Nasdaq
  • Market Cap
  • RELI 7.5M
  • CERO 6.1M
  • IPO Year
  • RELI N/A
  • CERO N/A
  • Fundamental
  • Price
  • RELI $1.01
  • CERO $5.39
  • Analyst Decision
  • RELI
  • CERO Strong Buy
  • Analyst Count
  • RELI 0
  • CERO 2
  • Target Price
  • RELI N/A
  • CERO $45.00
  • AVG Volume (30 Days)
  • RELI 11.7M
  • CERO 82.8K
  • Earning Date
  • RELI 11-06-2025
  • CERO 11-18-2025
  • Dividend Yield
  • RELI N/A
  • CERO N/A
  • EPS Growth
  • RELI N/A
  • CERO N/A
  • EPS
  • RELI N/A
  • CERO N/A
  • Revenue
  • RELI $14,061,478.00
  • CERO N/A
  • Revenue This Year
  • RELI N/A
  • CERO N/A
  • Revenue Next Year
  • RELI N/A
  • CERO N/A
  • P/E Ratio
  • RELI N/A
  • CERO N/A
  • Revenue Growth
  • RELI 1.07
  • CERO N/A
  • 52 Week Low
  • RELI $0.67
  • CERO $4.27
  • 52 Week High
  • RELI $5.11
  • CERO $895.40
  • Technical
  • Relative Strength Index (RSI)
  • RELI 53.73
  • CERO 40.84
  • Support Level
  • RELI $0.89
  • CERO $5.18
  • Resistance Level
  • RELI $1.15
  • CERO $5.45
  • Average True Range (ATR)
  • RELI 0.21
  • CERO 0.24
  • MACD
  • RELI 0.03
  • CERO 0.09
  • Stochastic Oscillator
  • RELI 23.31
  • CERO 56.96

About RELI Reliance Global Group Inc.

Reliance Global Group Inc operates as a holding company with diversified interests in the insurance market, as well as other related sectors. The company focuses on growing by pursuing acquisition strategies, initially and focused on wholesale and retail insurance agencies. Its primary strategies is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows. The company generates revenue in the form of commissions.

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

Share on Social Networks: